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Cardiogenic cerebral embolism represents 20% of all acute ischemic strokes (AISs) with
one-third of these being caused by left ventricular thrombus (LVT). LVT is not a contraindi-
cation for treatment with intravenous recombinant tissue plasminogen activator (IV rtPA)
for AIS. However, the subsequent treatment of a potentially unstable LVT is contraindi-
cated for 24 h following the use of IV rtPA according to current guidelines. We present
a 66-year-old man with AIS treated with IV rtPA. Echocardiogram shortly after treatment
demonstrated both a large apical and septal thrombus in the left ventricle and at 12 h post IV
rtPA infusion, therapeutic anticoagulationwith heparinwas startedwithout complication. In
practice, the action of IV rtPA outlasts its apparent half-life because of thrombin-binding and
the prolonged effects and longer half-life of its product, plasmin; however, the pharmaco-
kinetics do not warrant prolonged avoidance of therapeutic anticoagulation when clinically
indicated. Our case demonstrates that anticoagulation for potentially unstable LVT can be
safely initiated at 12 h following IV rtPA treatment for AIS.
Keywords: acute ischemic stroke, cardioembolic, thrombolysis, left ventricular thrombus, anticoagulation, rtPA,
alteplase, pharmacokinetics
INTRODUCTION
A 66-year-old man presented to our hospital with acute left sided
weakness, facial droop, slurred speech, and complete left hemi-
anopsia (NIHSS 6) within 90 min of symptom onset. His medical
history was remarkable for ischemic stroke a year prior with no
residual deficit and myocardial infarction (MI) 15 years prior com-
plicated by ventricular fibrillation requiring temporary balloon
pump. He had been discharged earlier that day from another
hospital where evaluation for shortness of breath revealed a left
ventricular thrombus (LVT). He was to initiate warfarin that
evening, which he had not yet commenced. The patient had no
contraindications to intravenous recombinant tissue plasminogen
activator (IV rtPA) and was treated within 60 min of presentation.
Magnetic resonance imaging (MRI) demonstrated acute
infarcts in both cerebral hemispheres (Figure 1) and no evi-
dence of hemorrhage. An apical LVT (2.4 cm× 1.4 cm) and
a second thrombus adjacent to the interventricular septum
(1.6 cm× 2.2 cm) were confirmed on transthoracic echocardio-
gram (TTE) (Figure 2) within 12 h of presentation and 10 h
of completion of IV rtPA infusion. Ejection fraction was 25%;
regional variation of wall motion and akinesis of the left ventricle
(LV) were also noted.
This presented a therapeutic conundrum whereby the presence
of a potentially high recurrent cardioembolic source required anti-
coagulation but was contraindicated due to recent administration
of IV rtPA. The patient’s activated partial thromboplastin time
(aPTT), prothrombin time (PT), and international normalized
ratio (INR) were verified to be within the normal range. The phar-
macokinetics of IV rtPA and its byproducts were reviewed and the
decision to start therapeutic anticoagulation was made. Non-bolus
IV heparin infusion was initiated 12 h after IV rtPA infusion. The
patient’s neurological deficit improved and he was bridged to war-
farin and discharged home with a favorable outcome (NIHSS 1,
modified Rankin Scale 1).
DISCUSSION
LVT AND CARDIOGENIC EMBOLISM
Cardiogenic embolism causes 20% of all ischemic strokes. While
non-valvular atrial fibrillation (AF) is responsible for approxi-
mately 50% of these cases, left ventricular mural thrombus rep-
resents almost one third of cases (1). The majority of LVT have
been associated with acute myocardial infarction (AMI), and also
occur in patients with chronic ventricular dysfunction from coro-
nary artery disease, hypertension, or dilated cardiomyopathy (1).
Myocardial injury can lead to severe regional wall motion abnor-
mality and hypokinesis, akinesis, dyskinesis, or aneurysmal dilata-
tion of the LV. Patients with large anterior MI have a high risk of
developing LVT and subsequent cardiogenic thromboembolism
(2). The incidence of embolic complications is highest in the first
1–3 months post-MI, with an absolute risk of 9% in patients with
acute MI complicated by LVT (3). Beyond the acute phase, patients
with persistent myocardial dysfunction have a 5-year stroke risk
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FIGURE 1 | Magnetic resonance imaging brain axial diffusion weighted
images demonstrating areas of restricted diffusion in the R occipital
lobe (A) and left superior frontal lobe (B).
FIGURE 2 |Transthoracic echocardiogram, apical 2 chamber view with
contrast demonstrating a left ventricular apical thrombus
(2.4 cm×1.4 cm) (top arrow) and a second thrombus (1.6 cm×2.2 cm)
(bottom arrow) adherent to the interventricular septum.
of 8% (4, 5). TTE is 23% sensitive and 96% specific for LVT detec-
tion (6), improving to 92% sensitivity when a high prevalence of
LVT was anticipated (7) and remains the preferred method for
detection. If image quality is poor or LVT risk is high with neg-
ative or equivocal echocardiography, contrast enhanced cardiac
MRI (CMR) should be considered. It has a sensitivity of 88% and
specificity of 99% (6).
The 2013 American College of Cardiology Foundation/
American Heart Association Guideline for the Management of
ST-elevation MI recommend vitamin K antagonist therapy for
3 months (2, 8) and perhaps indefinitely (9) with a goal INR of
2.0–3.0 if the risk of thromboembolism exceeds the bleeding risk
when LVT is demonstrated. This recommendation was based on
observational studies reporting better outcomes and fewer cerebral
emboli in patients treated with heparin and then transitioned to
warfarin. No guideline for prolonged duration of anticoagulation
exists and the decision is guided by follow-up echocardiography
and demonstration of resolution or persistence of the clot and
embolic risk as determined by the clinician.
Cardiomyopathy leading to impaired LV systolic function and
reduced stroke volume creates relative stasis and risk for LVT
development (5). Etiology of cardiomyopathy can be ischemia or
infarction, or non-ischemic causes such as genetic or acquired
structural or metabolic defects. Decreased ejection fraction and
older age are both independent risk factors for stroke after MI
(4). The warfarin versus aspirin in reduced cardiac ejection frac-
tion (WARCEF) trial showed fewer ischemic strokes in follow-up
for patients in sinus rhythm and ejection fraction <35% ran-
domized to warfarin compared to aspirin 325 mg daily; however,
the primary end point of ischemic stroke, intracerebral hem-
orrhage, or death was similar between groups (10). If LV dys-
function due to extensive regional wall motion abnormalities
is demonstrated, prophylactic treatment with warfarin may be
considered in patient with previous stroke or transient ischemic
attack (TIA) (1). Similarly, in patients with LVT in the set-
ting of congestive heart failure due to dilated cardiomyopathy,
anticoagulation might be reasonable particularly if the embolic
potential is high and the bleeding risk is low. This is supported
by indirect data from observational studies in patients with LVT
after MI (11).
No single clinical feature predicts embolic risk. Thrombi that
demonstrate mobility, protrusion, and central echolucency are
higher risk (12). A theoretical risk of embolization from desta-
bilization of a LVT after thrombolysis exists. However, only case
reports exist of post thrombolysis infarction in the contralateral
hemisphere (13). The largest case series of five patients did not
demonstrate subsequent re-embolization after IV thrombolysis
(14). The presence of LVT is not listed as a contraindication to IV
thrombolysis for acute ischemic stroke (AIS) according to current
guidelines (15).
IV rtPA KINETICS
Alteplase was FDA-approved for use in acute stroke in 1996 and
is also indicated for use in pulmonary embolism (PE) and AMI
(16, 17). It exerts its thrombolytic effects by converting plasmino-
gen to plasmin on clot-bound fibrin, in turn degrading fibrin clot
(18). This results in a 16–36% decrease in circulating fibrin and
16–62% decrease in fibrinogen (19). Alteplase has limited activity
in the absence of fibrin (20).
The elimination of alteplase is biphasic, reflecting a two-
compartment circulatory model (21–23). In healthy patients, there
is an alpha-phase with rapid decrease in plasma concentration
due to tissue distribution. The alpha-phase half-life (t1/2) ranges
from 3.3 to 6 min. The beta-phase is a slower decrease in plasma
concentration due to metabolism and excretion with a t1/2 of
26–40 min (24, 25). In patients with AMI, the alpha-phase t1/2
of alteplase is <5 min and the beta-phase t1/2 is 16–88 min (23,
26, 27). The majority of alteplase pharmacokinetic studies have
been conducted in AMI patients, who may have different elim-
ination characteristics compared to patients with AIS (18). The
mean age in many AMI studies is<60 years, and>45% of patients
who receive alteplase for AIS are >70 years (18, 28). Alteplase
metabolism may be slower in the elderly, contributing to increased
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hemorrhage risk (18, 29). Additionally, alteplase doses used in AMI
studies differ from the 0.9 mg/kg dose for AIS.
After alteplase administration, fibrinogen concentrations
return to 81% of pre-infusion values within 24 h (19, 23, 30). Plas-
minogen and alpha-2 antiplasmin demonstrate similar concen-
tration trends (70 and 35% of pre-infusion concentrations at 2 h
post-infusion, 83 and 88% at 24 h, respectively) (23). Fibrin degra-
dation products are found for upwards of 7 h in patients treated
with alteplase (31). Therefore, safe timing of antithrombotic ini-
tiation after alteplase treatment is uncertain. A study of 60 AIS
patients who received IV rtPA followed by 2850 units nadroparin
twice daily either immediately after rtPA or 24 h later found simi-
lar symptomatic intracranial hemorrhage rates at 36 h between the
two groups (early group 8.6 and 4% later group OR 1.8, 95% CI
0.5–3.2) (32). Sixteen (45.7%) early treatment and nine (36%)
standard treatment patients achieved a modified Rankin Scale
score of 0 or 1 at 3 months (OR 1.2, 95% CI 0.5–3.2) (32). Patients
with PE are generally treated with thrombolysis followed by imme-
diate anticoagulation with heparin, and in a trial comparing this
regimen to heparin alone, only one intracranial hemorrhage was
observed, in a patient who had sustained head trauma (33). Larger
trials investigating early versus delayed anticoagulation for AIS
patients who have received IV rtPA are needed.
CONCLUSION
Left ventricular thrombus can complicate both AMI and CHF with
dilated cardiomyopathy. These patients often have overlapping
risk factors for stroke and additional factors must be considered
in the management of AIS in this population. Additionally, with
increasing efficiency and expedited care at advanced stroke cen-
ters, ventricular thrombi may be increasingly discovered very early
in the patient’s post stroke care. LVT is not a contraindication
for treatment of AIS with IV rtPA. However, subsequent use of
therapeutic anticoagulation following thrombolysis within 24 h is
contraindicated. This case demonstrates that early anticoagula-
tion, 12 h post-thrombolytic infusion, can be safely administered.
Further evaluation of the safety of early anticoagulation for LVT
with high recurrent embolic potential following IV rtPA for AIS is
needed.
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